Ameloblastic carcinoma

Ameloblastic carcinoma (AC) is a rare malignant odontogenic epithelial neoplasm that combines the architectural features of ameloblastoma with overtly malignant cytologic characteristics.[1][2] It accounts for approximately 2% of odontogenic tumors and demonstrates aggressive local behavior with a significant propensity for metastasis.[2][3] AC arises most commonly in the posterior mandible, though maxillary involvement is well documented.[3] The tumor may develop de novo (primary type) or through malignant transformation of a pre-existing ameloblastoma (secondary type).[3][4] Radiographically, AC typically presents as an ill-defined radiolucency with cortical destruction and occasional focal radiopacities, contrasting with the well-defined multilocular pattern of conventional ameloblastoma.[1][3] Management centers on wide surgical excision with margins of 2–3 cm.[3][5]

The WHO 2017 (4th edition) classification consolidated AC into a single diagnostic entity, eliminating the prior 2005 subdivision into primary-type and secondary-type categories.[2][6] This reclassification was supported by comparative data demonstrating no significant differences in clinical behavior or survival between the two subtypes.[6] The term "ameloblastic carcinoma" was first recommended in 1982 and formally distinguished from "malignant (metastasizing) ameloblastoma" in 1984.[2] This distinction remains critical:

• Ameloblastic carcinoma: exhibits cytologic atypia and malignant histologic features regardless of metastatic status[1][7]
• Metastasizing ameloblastoma: metastasizes despite a histologically benign appearance; diagnosis is made only in retrospect[8]

Obsolete or ambiguous terms include "malignant ameloblastoma" (when used interchangeably with AC) and the former subclassifications "primary intraosseous type," "peripheral type," and "dedifferentiated type" from the 2005 WHO edition.[2] The term "atypical ameloblastoma" or "proliferative ameloblastoma" has been applied to lesions with increased mitotic activity and basaloid cell proliferation but lacking frank malignant features, representing a potential intermediate stage.[1]

• Frequency: AC is extremely rare. In a 20-year single-center study, 23 AC cases were identified among 1,258 ameloblastoma-like lesions (1.8%). A pooled individual patient data analysis identified 199 cases across 94 publications.[3][9]
• Age: Predominantly affects middle-aged and older adults. Median age is approximately 49–53 years, with a wide range (7–91 years). Approximately 70% of patients are older than 45 years.[3][9]
• Sex: Male predominance, with male-to-female ratios reported at 1.9:1 to 2.4:1.[3][9]
• Site: The posterior mandible (body, angle, ramus) is the most common location, accounting for approximately two-thirds of cases in pooled analyses. Maxillary involvement is reported in roughly 30–48% of cases, with some single-center series suggesting a higher maxillary proportion.[3][9]

Presentation and symptoms

The most common presenting complaint is swelling or a palpable mass, often in the posterior jaw.[3] Pain accompanies swelling in a subset of patients. Additional symptoms include:

• Tooth mobility and loosening
• Persistent non-healing ulceration of the overlying mucosa, particularly when traumatized by mechanical factors[3]
• Paresthesia or numbness of the lower lip or tongue when the inferior alveolar nerve is involved[3]
• Nasal symptoms (congestion, epistaxis) when maxillary tumors invade the nasal cavity or maxillary sinus[2][3]

Tempo and clinical behavior

Primary AC tends to present with a shorter disease course, whereas secondary AC typically has a prolonged history of ameloblastoma with prior surgical interventions and recurrences.[1][4] The secondary type is mainly seen in the seventh decade following a long history of ameloblastoma with multiple recurrences.[1] Rapid growth, cortical perforation, and soft tissue extension are hallmarks of aggressive behavior.[10][11]

Metastasis

Approximately 25% of AC cases metastasize.[12] The most common metastatic sites are regional cervical lymph nodes and the lungs.[2][3] Rare distant metastases to brain, bone, liver, and other sites have been reported.[13][14] Ameloblastomas with histologically confirmed extraosseous extension carry an increased risk of subsequent malignant transformation or metastasis.[15]

Location and distribution

AC occurs predominantly in the posterior mandible—body, angle, and ramus region—mirroring the distribution of conventional ameloblastoma.[1][3] Maxillary lesions most commonly involve the posterior maxilla and may extend into the maxillary sinus or nasal cavity.[2][3] Rare cases cross the midline in either jaw.[3]

Periphery and shape

The periphery is characteristically ill-defined and irregular, reflecting the infiltrative growth pattern of a malignant process.[1][3][12] This contrasts with the well-corticated or scalloped margins typical of conventional ameloblastoma. Some AC cases, particularly those arising within a pre-existing ameloblastoma, may retain partially well-defined borders in portions of the lesion, with ill-defined margins at the advancing front.[3]

Internal architecture

The internal pattern is most commonly a radiolucent destructive process. Recognized patterns include:

• Unilocular or multilocular radiolucency resembling ameloblastoma, sometimes described as honeycomb-like or cellular[3]
• Mixed cystic and solid changes on cross-sectional imaging, similar to ameloblastoma but often with more extensive solid components[2]
• Focal radiopacities representing dystrophic calcification—a distinctive feature that is unusual in benign ameloblastoma and should raise suspicion for malignancy[1][2][3][10]
• Extensive worm-eaten (vermicular) bone destruction suggesting aggressive behavior beyond that expected for ameloblastoma[2]

Effects on teeth and adjacent structures

• Root resorption: commonly observed, often more extensive and irregular than in ameloblastoma[3]
• Tooth displacement: adjacent teeth may be displaced by the expanding mass[3]
• Tooth mobility: clinically evident loosening of teeth within the tumor field[11]
• Inferior alveolar canal: mandibular lesions may widen, displace, or obliterate the canal, correlating with paresthesia[3]

Cortical involvement and extent

Cortical expansion with perforation is a hallmark feature, distinguishing AC from the expansile but typically intact cortex of early ameloblastoma.[1][3][10] Findings include:

• Buccolingual or labiolingual cortical expansion and thinning
• Cortical perforation with extension of tumor into surrounding soft tissues
• Maxillary lesions may erode through the sinus floor, palatal bone, or nasal floor[2]

CBCT and contrast-enhanced CT are particularly valuable for demonstrating cortical perforation, soft tissue extension, and internal dystrophic calcification—features that may not be fully appreciated on panoramic radiography alone.[3][16]

Peripheral (extraosseous) variant

The rare peripheral type of AC presents as a soft tissue gingival mass with compressive resorption of the underlying cortical bone rather than an intraosseous destructive lesion.[3] Characteristic intraosseous imaging features are absent, making radiographic diagnosis challenging.[3]

CT (medical)

Contrast-enhanced medical CT demonstrates the mixed cystic and solid nature of the tumor, with enhancing solid components and non-enhancing cystic or necrotic areas.[2][17] Osteolytic destruction with dystrophic calcification is a characteristic CT finding.[2] CT is superior for evaluating cortical bone erosion and perforation and for assessing extension into the maxillary sinus, nasal cavity, orbit, or skull base.[18][19]

MRI

MRI provides superior soft tissue contrast for delineating tumor extent, marrow invasion, and the relationship to neurovascular structures.[19][20] MRI is preferred when perineural spread along the inferior alveolar nerve or other cranial nerves is suspected, and for distinguishing tumor from retained secretions in the maxillary sinus.[19] On contrast-enhanced MRI, solid tumor components enhance, aiding differentiation from cystic areas.[17]

PET/CT

FDG-PET/CT has been reported in isolated cases of AC with metastatic disease, demonstrating FDG-avid primary and metastatic lesions.[13] Its role is primarily in staging when distant metastasis is suspected and for surveillance in high-risk cases.

Ameloblastic carcinoma must be distinguished from other aggressive radiolucent or mixed jaw lesions. The imaging overlap with ameloblastoma is substantial, and definitive differentiation requires histopathologic examination. Key alternatives include:

The highest-risk diagnostic pitfall is misidentifying AC as conventional ameloblastoma, particularly in secondary AC where benign and malignant areas coexist. Biopsy with adequate sampling is essential, and immunohistochemistry for Ki-67 and p53 can support the distinction when cytologic atypia is equivocal.[1][21]

Diagnostic features

The defining histologic criterion is the combination of ameloblastic architectural differentiation with overtly malignant cytology:[1][7]

• Ameloblastic architecture: epithelial islands and plexiform strands with at least focal peripheral palisading of columnar or cuboidal cells showing reverse nuclear polarity[1][12]
• Malignant cytology: cellular and nuclear pleomorphism, nuclear hyperchromatism, increased mitotic activity, hypercellularity, and apoptotic bodies[1][12]
• Supportive features: focal necrosis, perineural invasion, and vascular invasion[1][12]

Classic stellate reticulum-like areas may be present but are not always prominent; in one series, they were identified in only 17% of cases.[2]

Histologic variants and special features

• Squamous differentiation: observed in approximately 27% of cases with adequate histologic description; does not appear to alter clinical behavior[22]
• Clear cell component: occasionally prominent and may cause confusion with clear cell odontogenic carcinoma; clear cell AC may carry a higher recurrence risk[1][2]
• Dystrophic calcification: an unusual feature in ameloblastoma that supports malignancy when present[2]
• Spindle cell variant: rarely reported, adding diagnostic complexity[1]

Immunohistochemistry and molecular findings

• Ki-67 and p53: significantly higher expression in AC than ameloblastoma, useful as diagnostic adjuncts[1][3][21]
• BRAF V600E mutation: detected in tested AC cases and associated with aggressive behavior[3][23]
• Additional markers: CK5, CK14, and CK19 are positive in both ameloblastoma and AC, but expression patterns of CK5 and CK19 differ in malignant cells. p63 expression is higher in AC. NM23 expression and p16 CpG methylation have also been linked to AC.[3][21]

Radiologic-pathologic correlation

Focal radiopacities on imaging correspond to dystrophic calcification histologically—a feature distinctly unusual in benign ameloblastoma.[1][2] Ill-defined radiographic margins correlate with infiltrative tumor borders, perineural invasion, and soft tissue extension seen microscopically.[3][12]

Workup and staging

Incisional biopsy with adequate tissue sampling is mandatory for definitive diagnosis, as clinical and radiographic features alone cannot reliably distinguish AC from ameloblastoma.[3][11] Preoperative imaging should include contrast-enhanced CT or MRI for assessment of tumor extent, cortical integrity, and soft tissue invasion.[18][19] Chest imaging (CT) is recommended to evaluate for pulmonary metastasis, the most common distant metastatic site.[2][15] Selective neck imaging or examination is warranted when cervical lymphadenopathy is suspected.

Surgical treatment

Wide surgical excision with clear margins of 2–3 cm of normal bone is the primary treatment.[3][5] Extended resection with flap reconstruction is associated with lower recurrence and mortality compared with conservative resection.[3] Positive surgical margins are a key factor contributing to recurrence.[3]

• Lymph node dissection: selective neck dissection should be performed when there is clinical or radiographic evidence of lymph node metastasis; routine prophylactic neck dissection is not supported by current evidence given the low incidence of cervical nodal involvement.[3][11]

Adjuvant therapy

• Radiotherapy: does not confer a clear survival advantage for patients with localized disease and younger age; however, older patients with high-risk features (positive margins, perineural invasion) may benefit from adjuvant radiation. Preoperative radiotherapy has been suggested to reduce tumor size in select cases.[2][9]
• Chemotherapy: the role remains unclear and is not routinely recommended.[2][11]

Recurrence and prognosis

• Recurrence rate: approximately 17–26% across reported series, occurring from 3 months to over 12 years postoperatively[2][3]
• Survival: five-year overall survival is approximately 63–69%, with median overall survival of 122 months in pooled analysis. Three-year survival is approximately 79%.[3][9]
• Prognostic factors: R0 resection is the strongest favorable prognostic factor. Metastasis and recurrence are the most significant adverse determinants of survival. The secondary type may carry a worse prognosis than the primary type, though comparative studies have also shown no significant survival difference.[2][4][6][9]

Surveillance

Long-term follow-up is essential, as recurrence may occur more than a decade after initial treatment.[2][14] Periodic clinical examination and imaging—including chest CT for pulmonary surveillance—are recommended.[2][15]

BRAF V600E and targeted therapy

The BRAF V600E mutation has been identified in AC and is associated with more aggressive tumor behavior.[23] This finding raises the possibility of targeted therapy with BRAF inhibitors (e.g., vemurafenib, dabrafenib) as a future treatment direction, though clinical evidence in AC remains limited to preclinical rationale and case-level observations.[23][24] BRAF V600E is also prevalent in conventional ameloblastoma, where it has been incorporated into the WHO molecular classification framework.[24]

Malignant transformation of ameloblastoma

The 5-year rate of malignant transformation from ameloblastoma to AC is estimated at approximately 3%.[15] Ameloblastomas with histologically confirmed extraosseous extension carry a significantly increased risk of transformation (HR 3.9) and warrant closer surveillance including thoracic imaging.[15] Atypical ameloblastoma, characterized by increased mitotic activity without frank malignancy, may represent a precursor lesion; in one series, 2 of 31 atypical ameloblastoma patients subsequently developed AC.[3]